Previous studies have demonstrated that gastric cancers with homologous recombination defects (HRD) exhibit heightened sensitivity to DNA damage‐based chemotherapy, particularly platinum‐based drugs [38], whereas MMR‐deficient tumors are more likely to be resistant to fluorouracil‐based chemotherapy [39]. Here, MRC1 is linked to gastric cancer.